2. Academic Validation
  3. MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity

MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity

  • Cell Metab. 2022 Nov 1;34(11):1732-1748.e5. doi: 10.1016/j.cmet.2022.10.007.
Dong Cheng 1,  Bradley A Zinker 2,  Yi Luo 3,  Petia Shipkova 4,  Claudia H De Oliveira 5,  Gopal Krishna 6,  Elizabeth A Brown 7,  Stephanie L Boehm 2,  Giridhar S Tirucherai 8,  Huidong Gu 3,  Zhengping Ma 2,  Ching-Hsuen Chu 2,  Joelle M Onorato 4,  Lisa M Kopcho 9,  Ron Ammar 7,  Julia Smith 2,  Pratik Devasthale 10,  R Michael Lawrence 10,  Steven A Stryker 4,  Elizabeth A Dierks 4,  Anthony V Azzara 2,  Leon Carayannopoulos 6,  Edgar D Charles 5,  Kimberley A Lentz 4,  David A Gordon 2
Affiliations

Affiliations

  • 1 Departments of Discovery Biology Cardiovascular and Fibrosis, Bristol Myers Squibb, Princeton, NJ 08543, USA. Electronic address: dong.cheng@bms.com.
  • 2 Departments of Discovery Biology Cardiovascular and Fibrosis, Bristol Myers Squibb, Princeton, NJ 08543, USA.
  • 3 Translational Medicine, Bristol Myers Squibb, Lawrenceville, NJ 08543, USA.
  • 4 Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ 08543, USA.
  • 5 Global Drug Development, Bristol Myers Squibb, Lawrenceville, NJ 08543, USA.
  • 6 ICF Early Clinical Development, Bristol Myers Squibb, Summit, NJ 07901, USA.
  • 7 Translational Bioinformatics, Bristol Myers Squibb, Princeton, NJ 08543, USA.
  • 8 Clinical Pharmacology, Bristol Myers Squibb, Lawrenceville, NJ 08543, USA.
  • 9 Leads Discovery and Optimization, Bristol Myers Squibb, Princeton, NJ 08543, USA.
  • 10 Small Molecule Drug Discovery, Bristol Myers Squibb, Princeton, NJ 08543, USA.
PMID: 36323235 DOI: 10.1016/j.cmet.2022.10.007
Abstract

Monoacylglycerol Acyltransferase 2 (MGAT2) is an important Enzyme highly expressed in the human small intestine and liver for the regulation of triglyceride absorption and homeostasis. We report that treatment with BMS-963272, a potent and selective MGAT2 Inhibitor, decreased inflammation and fibrosis in CDAHFD and STAM, two murine nonalcoholic steatohepatitis (NASH) models. In high-fat-diet-treated cynomolgus monkeys, in contrast to a selective diacylglycerol Acyltransferase 1 (DGAT1) inhibitor, BMS-963272 did not cause diarrhea. In a Phase 1 multiple-dose trial of healthy human adults with obesity (NCT04116632), BMS-963272 was safe and well tolerated with no treatment discontinuations due to adverse events. Consistent with the findings in rodent models, BMS-963272 elevated plasma long-chain dicarboxylic acid, indicating robust pharmacodynamic biomarker modulation; increased gut Hormones GLP-1 and PYY; and decreased body weight in human subjects. These data suggest MGAT2 inhibition is a promising therapeutic opportunity for NASH, a disease with high unmet medical needs.

Keywords

DCA; DGAT; GLP-1; MGAT2; NAFLD; NASH; PYY; dicarboxylic acid; liver fibrosis; steatosis; weight loss.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z